[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649621":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":33,"locations":39,"responsibleParty":55,"collaborators":11,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":59,"sex":65,"minAge":66,"maxAge":11,"enrollmentInfo":67,"targetDuration":11,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":79,"whyStopped":11,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"CT-Guided, mpMRI Assisted Whole Prostate SBRT","ACTIVE_COMPARATOR",null,[13],"Radiation: Stereotactic Body Radiation Therapy",{"label":15,"type":16,"description":11,"interventionNames":17},"CT-Guided Prostate SBRT with Microultrasound-Guided Dominant Intraprostatic Lesion Boost","EXPERIMENTAL",[13,18],"Device: ExactVu",[20,25,28],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"RADIATION","Stereotactic Body Radiation Therapy","Standard whole prostate stereotactic body radiation therapy (40 Gray\u002F5 fractions given on alternate days)",[9],{"type":21,"name":22,"description":26,"armGroupLabels":27,"otherNames":11},"Micro-boost to the dominant intraprostatic lesions (DILs) of 40 Gray, with the rest of the prostate receiving 35 Gray. If no DILs identified, whole prostate stereotactic body radiation therapy with dose of 35 Gray. Both interventions to be given in 5 fractions on alternate days.",[15],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":11},"DEVICE","ExactVu","microUltrasound",[15],[34],{"name":35,"role":36,"phone":37,"phoneExt":11,"email":38},"Lucas Mendez, MD","CONTACT","519-685-8500","Lucas.Mendez@lhsc.on.ca",[40],{"facility":41,"status":11,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"London Health Sciences Centre, Verspeeten Family Cancer Centre","London","Ontario","N6A 5W9","Canada","CA",{"type":48,"coordinates":49},"Point",[50,51],-81.23304,42.98339,{"lat":51,"lon":50},[54],{"name":35,"role":36,"phone":37,"phoneExt":11,"email":38},{"type":56,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100649621","micro-ultrasound-guided-prostate-sbrt-100649621",false,"NCT07737457","MICRO-ultrasound Guided Prostate SBRT","MICRO-ultrasound Guided Prostate SBRT (MICRO-S)","MICRO-S","Inclusion Criteria:\n\n* Histologically confirmed carcinoma of the prostate (biopsy results with 12 months of enrollment)\n* Intermediate risk as defined by NCCN criteria\n* Conventional imaging (bone scan and abdominal pelvic computed tomography) is mandatory for NCCN unfavourable intermediate risk prostate cancer patients with PSA \\> 10. Negative nodal, skeletal or visceral metastases within 16 weeks of enrollment (for patients requiring staging). Alternatively, patients with no signs of extra-prostatic disease on PSMA-PET scans are also candidates for this trial\n* ECOG performance status 0-1\n* Willing to give informed consent to participate in this clinical trial\n* Able and willing to complete QOL questionnaires Most responsive physician definition if androgen deprivation therapy will be used (only allowed for NCCN unfavourable intermediate risk prostate cancer)\n\nExclusion Criteria:\n\n* Estimated prostate volume \\> 60cc (volume based on transrectal ultrasound)\n* Prior TURP\n* Prior prostate cancer treatment, including 5-alpha reductase inhibitor treatment\n* Low, high or very high-risk disease as per NCCN guidelines\n* Connective tissue disease or inflammatory bowel disease\n* Contraindication to prostate microUS\n* Men with double hip prostheses\n* Contraindication for MRI (i.e. non-compatible stent, pacemaker, prosthesis etc.)\n* Anticoagulation medication (if unsafe to discontinue for fiducial marker insertion)\n* Diagnosis of bleeding diathesis","MALE","18 Years",{"count":68,"type":69},112,"ESTIMATED","INTERVENTIONAL",[72],"NA","This study will test whether it is safe and effective to use stereotactic body radiation therapy (SBRT)-a short, targeted form of radiation-together with a microultrasound (microUS)-guided radiation boost to the cancerous spots inside the prostate. Researchers will compare treatment plans that use microUS to plans created using the current standard method, which relies on MRI images, to determine whether microUS can successfully guide targeted radiation.",[75],"Prostate Cancer",[77,78],"Intermediate risk prostate cancer","Prostate carcinoma","NOT_YET_RECRUITING","2026-07-27",{"date":82,"type":83},"2026-07-30","ACTUAL",{"date":85,"type":69},"2026-09",{"date":87,"type":69},"2033-03",{"name":5,"class":6},1]